An approved GHRH analog — useful contrast to unapproved research secretagogues.
Also known as: Egrifta
Part of the Growth hormone & IGF peptides cluster
Overview
Tesamorelin is a synthetic growth hormone–releasing hormone analog approved in some countries for specific labeled indications. It is an important benchmark in GHRH-analog education.
Source & context
Biological / chemical source: Synthetic GHRH analog
Primary research or clinical context: Approved in some markets for specific HIV-associated indications
Approved vs research landscape
Tesamorelin illustrates how a GHRH pathway peptide can become a regulated medicine with defined indications, manufacturing standards, and labeling — unlike many research-only secretagogues.
FAQ about Tesamorelin
What is Tesamorelin?+
Tesamorelin is a synthetic growth hormone–releasing hormone analog approved in some countries for specific labeled indications. It is an important benchmark in GHRH-analog education.
Is Tesamorelin an approved medicine?+
Tesamorelin: Approved in some markets for specific HIV-associated indications. Always follow licensed medical guidance for approved products.
What is the typical length of Tesamorelin?+
Tesamorelin is commonly described as approximately 44 amino acids (GHRH analog).
Related peptides
References & further reading
- 1.Wikipedia — Tesamorelin
- 2.PubChem — compound summary for Tesamorelin (CID 16137828)
- 3.Falutz et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med
- 4.Falutz et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr
- 5.Stanley et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA
- 6.Stanley et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV
- 7.Fourman et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight
- 8.Baker et al. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol
- 9.Russo et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS
- 10.Fourman et al. (2017). Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS
- 11.Rahman et al. (2023). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci
- 12.Bedimo (2011). Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl)
- 13.Spooner et al. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother
- 14.Stanley et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis